Company Overview and News
With oil price recovery taking hold, several U.S. oil and gas companies entered 2018 with a compelling plan - sell undeveloped or less essential fields and invest the money to boost returns from their sweetest, most productive spots.
BLT WLL BHPBF PVAYQ QEP DVN PVA OAS BHP PVAC BBL BHP BHPLF
Shares of Chevron Corporation (CVX - Free Report) , which has survived the worst oil crash in more than 50 years, now sit near 52-week highs. The blue-chip energy company is up more than 100% off its August 2015 lows and poised for further capital appreciation, riding on its healthy earnings growth prospects.
RDS.B RDS.A WLL XOM CVX RYDBF LMHA RDSB RDSA RYDAF LMHB LM
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
COF.PRG COF.PRH COF-P UNP WLL XOM COF.WS COF.PRP QSII COF UTX COF-D COF-C COF-F CVX ED COF.PRC OXY DAL COF.PRD COF.PRF
Launched on 12/23/2014, the PowerShares Russell 1000 Equal Weight Portfolio (EQAL - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Blend segment of the US equity market.
PBF IVV WLL EQAL HFC IVV
On Jun 11, we issued an updated research report on NCI Building Systems, Inc. (NCS - Free Report) . The company is poised to gain from bookings and backlog strength, and encouraging economic indicators. Focus on growth strategy around Insulated Metal Panels (IMP), investments in automation and process innovation, and favorable seasonal factors also bode well. Let’s illustrate these growth factors in detail.
PVH IBP WLL PATK UTX NCS
Equinor ASA (EQNR - Free Report) along with its partners is contemplating the idea of supplying power from land to three platforms. These include Troll C and the Sleipner field center that comprises the Gudrun tie-in platform in the North Sea. Currently, these three platforms are powered by gas turbines. The company is planning to lower CO2 emissions by more than 600,000 tons annually from Troll C and the Sleipner area.
PVH WLL CVRR UTX OXY
In a bid to provide the most comprehensive and flexible Internet of Things (IoT) offerings in the industrial space, Rockwell Automation, Inc. (ROK - Free Report) has entered into a definitive agreement for a strategic partnership with PTC Inc. (PTC - Free Report) . Per the deal, Rockwell Automation will invest $1 billion in PTC as both companies will join forces to drive growth through digital technology.
PTC PVH CATR WLL CAT UTX AAXN ROK
Nokia Corporation (NOK - Free Report) has announced that it will be launching a new 5G design concept and deployment services, which will help operators reduce time-to-market cost effectively. The company also revealed its successful completion of an end-to-end 5G New Radio (NR) data call in China. The 3GPP-compliant dual connectivity trial was conducted by the 5G Technology R&D team of the Chinese Ministry of Industry and Information Technology (“MIIT”).
MSI PVH CMTL WLL NOKIA UBNT NOK UTX
Whiting Petroleum Corporation (WLL - Free Report) has been a preferred pick for investors lately. The shares of the company have rallied 76% over the past three months, while the stocks in this industry have collectively gained just 10%.
PVH OAS WLL WRD UTX GPRK
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...
Silicon Investor Message Boards
This table lists all message boards related to WLL / Whiting Petroleum Corp. on message board site Silicon Investor.
|NWLL||Wellco Energy Services Inc WLL $0.27|
|Welco WLL,V and Fairline FAF,A||Action Sports Ltd.(Let the games begin!) WLLO|
as of ET